





























Supplementary Figure 2. Recommended atlas of the tympanic cavity, Eustachian tube (ET), cochlea, IAC, TMJ, temporal lobe, brainstem, parotid gland, spinal cord, optic nerve, chiasm, submandibular gland, pituitary, mandible, eyes, lens, brachial plexus, tongue(oral cavity), larynx, pharyngeal constrictors and trachea as OARs based on CT-MRI fusion in NPC patients.



Supplementary References 1: The list of literatures relative to OARs contouring

1. Baxi S, Park E, Chong V, Chung HT. Temporal changes in IMRT contouring of organs at risk for nasopharyngeal carcinoma - the learning curve blues and a tool that could help. *Technol Cancer Res Treat* 2009; 8:131-140.
2. Gondi V, Tome WA, Rowley HA, Mehta MP. Hippocampal Contouring: A Contouring Atlas for RTOG 0933. 2011.
3. Penumetcha N, Kabadi S, Jedynak B, et al. Feasibility of geometric-intensity-based semi-automated delineation of the tentorium cerebelli from MRI scans. *J Neuroimaging* 2011; 21:e148-55.
4. Chau RM, Leung SF, Kam MK, et al. A split-organ delineation approach for dose optimisation for intensity-modulated radiotherapy for advanced T-stage nasopharyngeal carcinoma. *Clin Oncol (R Coll Radiol)* 2008; 20:134-41.
5. Bonilha L, Kobayashi E, Cendes F, Li LM. The importance of accurate anatomic assessment for the volumetric analysis of the amygdala. *Braz J Med Biol Res* 2005; 38:409-18.
6. Wang SZ, Yan XJ, Guo M, et al. Clinical analysis of otitis media with effuse after 3D planning system based radiotherapy of nasopharyngeal carcinoma. *China Oncol* 2006; 16:503-7.
7. Walker GV, Ahmed S, Allen P, et al. Radiation-induced middle ear and mastoid opacification in skull base tumors treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2011; 81:e819-e823.
8. Wang SZ, Wang WF, Guo M, et al. Analysis of anatomic factors controlling the morbidity



Raccomandazioni per il contouring del rinofaringe

- of radiation-induced otitis media with effusion. *Radiotherapy and Oncology* 2007; 85: 463–468.
9. Wang SZ, Li J, Miyamoto CT, et al. A study of middle ear function in the treatment of nasopharyngeal carcinoma with IMRT technique. *Radiotherapy and Oncology* 2009; 93:530-3.
 10. Hsin CH, Chen TH, Young YH, Liu WS. Comparison of otologic complications between intensity-modulated and two-dimensional radiotherapies in nasopharyngeal carcinoma patients. *Otolaryngology-Head and Neck Surgery* 2010; 143: 662-8.
 11. Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. Ototoxicity after radiotherapy for head and neck tumors. *Int J Radiat Oncol Biol Phys* 2007; 67:469-79.
 12. Petsuksiri J, Sermsree A, Thephamongkhol K, et al. Sensorineural hearing loss after concurrent chemoradiotherapy in nasopharyngeal cancer patients. *Radiat Oncol* 2011; 6:19.
 13. Pacholke HD, Amdur RJ, Schmalfuss IM, Louis D, Mendenhall WM. Contouring the middle and inner ear on radiotherapy planning scans. *Am J Clin Oncol* 2005; 28:143-147.
 14. Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. *Int J Radiat Oncol Biol Phys* 2005; 61:1393-1402.
 15. Low WK, Burgess R, Fong KW, Wang DY. Effect of radiotherapy on retro-cochlear auditory pathways. *Laryngoscope* 2005; 115:1823-1826.
 16. Chen WC, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. *Cancer* 2006; 106 (Suppl. 4):820-829.



Raccomandazioni per il contouring del rinofaringe

17. Bhandare N, Jackson A, Eisbruch A, Radiation therapy and hearing loss. *Int J Radiat Oncol Biol Phys* 2010; 76:S50-7.
18. Zuur CL, Simis YJ, Lamers EA, et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors. *Int J Radiat Oncol Biol Phys* 2009; 74:490-6.
19. Parashar B, Kuo C, Kutler D, et al. Importance of contouring the cervical spine levels in initial intensity-modulated radiation therapy radiation for head and neck cancers: implications for re-irradiation. *J Cancer Res Ther* 2009; 5:36-40.
20. Kong FM, Ritter T, Quint DJ, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. *Int J Radiat Oncol Biol Phys* 2011; 81:1442-1457.
21. Leung WM, Tsang NM, Chang FT, Lo CJ. Lhermitte's sign among nasopharyngeal cancer patients after radiotherapy. *Head Neck* 2005; 27:187-194.
22. Harari PM, Song S, Tome WA. Emphasizing Conformal Avoidance vs. Target Definition for IMRT Treatment Planning in Head and Neck Cancer. *Int J Radiat Oncol Biol Phys* 2010; 77: 950–958.
23. Ezhi M, Starkschall G, Mohan R, Cox J, Komski R. Validation of a model-based segmentation approach to propagating normal anatomic regions of interest through the 10 phases of respiration. *Int J Radiat Oncol Biol Phys* 2008; 71: 900-6.
24. Weiss W, Wijesooriya K, Ramakrishnan V, Keall P. Comparison of intensity-modulated radiotherapy planning based on manual and automatically generated contours using deformable image registration in four-dimensional computed tomography of lung cancer



Raccomandazioni per il contouring del rinofaringe

- patients. *Int J Radiat Oncol Biol Phys* 2008; 70: 572–581.
25. Qatarneh SM, Noz ME, Hyodymaa S, Maguire GQ, Kramer EL, Crafoord J. Evaluation of a segmentation procedure to delineate organs for use in construction of a radiation therapy planning atlas. *Int J Med Inform* 2003; 69: 39-55.
 26. Pak D, Vineberg K, Feng F, Ten Haken RK, Eisbruch A. Lhermitte sign after chemo-IMRT of head-and-neck cancer: incidence, doses, and potential mechanisms. *Int J Radiat Oncol Biol Phys* 2012; 83(5):1528-33.
 27. Uhl M, Sterzing F, Habl G, et al. CT-myelography for high-dose irradiation of spinal cord and paraspinal tumors with helical tomotherapy: revival of an old tool. *Strahlenther Onkol* 2011; 187:416-20.
 28. Brouwer CL, Steenbakkers RJ, Van den Heuvel E, et al. 3D Variation in delineation of head and neck organs at risk. *Radiat Oncol* 2012; 7:32.
 29. Schreibmann E, Fox T. Towards automated planning for unsealed source therapy. *J Appl Clin Med Phys* 2012; 13:3789.
 30. Urbano TG, Clark CH, Hansen VN, et al. Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: Acute toxicity results of a phase I study. *Radiation Oncol* 2007; 85:58-63.
 31. Zwicker F, Roeder F, Hauswald H, et al. Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. *Head Neck* 2011; 33:1695-702.
 32. Park SH, Park HC, Park SW, et al. Multi-institutional Comparison of Intensity Modulated Radiation Therapy (IMRT) Planning Strategies and Planning Results for Nasopharyngeal Cancer. *J Korean Med Sci* 2009; 24:248-55.



Raccomandazioni per il contouring del rinofaringe

33. Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. *Int J Radiat Oncol Biol Phys* 2004; 59:28-42.
34. Claus F, Duthoy W, Boterberg T, et al. Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience. *Oral Oncol* 2002; 38:597-604.
35. Chen AM, Li BQ, Farwell DG, Marsano J, Vijayakumar S, Purdy JA. Improved dosimetric and clinical outcomes with intensity-modulated radiotherapy for head-and-neck cancer of unknown primary origin. *Int J Radiat Oncol Biol Phys* 2011; 79:756-62.
36. Dirix P, Nuyts S. Evidence-based organ-sparing radiotherapy in head and neck cancer. *Lancet Oncol* 2010; 11:85-91.
37. Strigari L, Benassi M, Arcangeli G, Bruzzaniti V, Giovinazzo G, Marucci L. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 2010; 77:269-76.
38. Zhang Y, Lin J, Zhou W, Tang J, Liao Y. Dosimetric verification and clinical efficacy of intensity modulated radiotherapy in nasopharyngeal carcinoma. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 2009;34: 879-85
39. van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJ, Rasch CR. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. *Radiat Oncol* 2008; 3:41.
40. Huang K, Xia P, Chuang C, Weinberg V, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San



Raccomandazioni per il contouring del rinofaringe

- Francisco experience. *Cancer* 2008; 113:497-507.
41. Seung S, Bae J, Solhjem M, et al. Intensity-modulated radiotherapy for head-and-neck cancer in the community setting. *Int J Radiat Oncol Biol Phys* 2008; 72:1075-81.
 42. Bhide S, Clark C, Harrington K, Nutting CM. Intensity Modulated Radiotherapy Improves Target Coverage and Parotid Gland Sparing When Delivering Total Mucosal Irradiation in Patients With Squamous Cell Carcinoma of Head and Neck of Unknown Primary Site *Med Dosim* 2007; 32:188-95.
 43. Guerrero Urbano MT, Clark CH, et al. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. *Clin Oncol (R Coll Radiol)* 2007; 19:604-13.
 44. Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 2006; 66:966-74.
 45. Braam PM, Terhaard CH, Roesink JM, Raaijmakers CP. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. *Int J Radiat Oncol Biol Phys* 2006; 66:975-80.
 46. de Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. *Int J Radiat Oncol Biol Phys* 2006; 64:363-73.
 47. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. *Cancer* 2004; 101:1584-93.



Raccomandazioni per il contouring del rinofaringe

48. Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. *Int J Radiat Oncol Biol Phys* 2004; 59:43-50.
49. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2004; 58:663-73.
50. van Asselen B, Dehnad H, Raaijmakers CP, Roesink JM, Lagendijk JJ, Terhaard CH. The dose to the parotid glands with IMRT for oropharyngeal tumors: the effect of reduction of positioning margins. *Radiother Oncol* 2002; 64:197-204.
51. Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. *Int J Radiat Oncol Biol Phys* 2002; 53:12-22.
52. Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. *Int J Radiat Oncol Biol Phys* 2000; 48:711-22.
53. Wu Q, Manning M, Schmidt-Ullrich R, Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. *Int J Radiat Oncol Biol Phys* 2000; 46:195-205.
54. Butler EB, Teh BS, Grant WH 3rd, et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head



Raccomandazioni per il contouring del rinofaringe

- and neck cancer with intensity modulated radiotherapy. *Int J Radiat Oncol Biol Phys* 1999; 45:21-32.
55. Grégoire V, Jeraj R, Lee JA, O'Sullivan B. Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive? *Lancet Oncol* 2012; 13:e292-300.
56. Scrimger R. Salivary gland sparing in the treatment of head and neck cancer. *Expert Rev Anticancer Ther* 2011; 11:1437-48.
57. Anand AK, Jain J, Negi PS, et al. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy. *Clin Oncol (R Coll Radiol)* 2006; 18:497-504.
58. Faggiano E, Fiorino C, Scalco E, et al. An automatic contour propagation method to follow parotid gland deformation during head-and-neck cancer tomotherapy. *Phys Med Biol* 2011; 56:775-91.
59. Feng M, Demiroz C, Karen A, et al. Normal Tissue Anatomy for Oropharyngeal Cancer: Contouring Variability and Its Impact on Optimization. *Int J Radiat Oncol Biol Phys*, 2012; 84:e245-9.
60. Mukesh M, Benson R, Jena R, et al. Interobserver variation in clinical target volume and organs at risk segmentation in post-parotidectomy radiotherapy: can segmentation protocols help? *The British Journal of Radiology* 2012; 85: e530–e536.
61. Loo SW, Martin WM, Smith P, Cherian S, Roques TW. Interobserver variation in parotid gland delineation: a study of its impact on intensity-modulated radiotherapy solutions with a systematic review of the literature. *Br J Radiol* 2012; 85:1070-7.